Background: A British randomised study of gemcitabine plus cisplatin (GC) combination
showed promising results in biliary tract cancer (BTC) patients. In our study, we evaluated the …

To determine the effect of intravenous recombinant tissue plasminogen activator (rt-PA) on
vascular and neurologic outcomes, we enrolled 31 patients with acute carotid artery-territory …

Background Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF)
receptors 1, 2, and 3. A randomised phase 2 trial of gemcitabine with or without axitinib in …

… weight by using the following equation: (1) GNRI = [ 1.489 × albumin ( g / dL ) ] + [ 41.7 × (
body wt / ideal body wt ) ] Body weight or ideal body weight was set to 1 when the patient’s …

Ramelteon (TAK-375) is a novel melatonin receptor agonist currently under investigation for
the treatment of insomnia. This study describes the neurochemical and receptor binding …

Functional graded materials (FGM) provided us one new concept for guided tissue regeneration
(GTR) membrane design with graded component and graded structure where one face …

… Patients were randomly assigned to receive only gemcitabine (1,000 mg/m2 on days 1, 8,
and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on …

… (B) Maximum of first assembly (t = 258 s). Note the dense … (C) Assembly minimum following
the first maximum (t = 403 s). … (D) Second assembly maximum (t = 482 s). Note that some …

… ) [11], were selected from our institute’s dementia registry. The mean age of the AD group …
± 0.8) were selected randomly from our institute’s normal registry. All control subjects had no …

This double-blind, phase 3 study assessed the efficacy and safety of ganitumab plus
gemcitabine as first-line treatment of metastatic pancreatic cancer. The study was stopped after a …